Digital Health Focus Feel Therapeutics is a Digital Precision Medicine company targeting mental and behavioral health, offering objective data, passive monitoring, and digital biomarkers which can complement or substitute traditional care pathways and create new DTx opportunities for payers and providers.

Wearable AI Recent launch of a wearable device paired with AI for emotional and mental health suggests a tangible entry point for remote monitoring, patient engagement, and data-driven decision support that can be packaged as a standalone solution or integrated with existing therapies.

Strategic Partnerships Backed by Felicis, Anthemis, and SOSV and collaborations with large pharmaceutical companies indicate strong validation and potential co-development or co-marketing opportunities for digital biomarkers, go-to-market programs, and data-driven clinical trials.

Clinical Platform Maturity A Digital Precision Medicine Platform launched in 2022, with ongoing development of digital biomarkers and digital therapeutics (DTx), points to a scalable, product-ready offering that can be positioned to health systems, payers, and pharma as a modern mental health solution.

Financial Readiness Funding of 14 million with revenue under 1 million signals an opportunity to position pilots or early-adopter engagements with risk-sharing or outcome-based models to accelerate adoption and demonstrate value to investors and customers.